Unaudited financial results for the quarter ended on June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals Ltd reported standalone revenue from operations of ₹94.37 crore in Q1FY26, up 2.5% year-on-year from ₹92.06 crore and 17.6% sequentially from ₹80.28 crore. Standalone net profit was ₹10 crore versus ₹12.18 crore in Q1FY25, a decline of about 18%, with EPS at ₹14.51 vs ₹20.26. EBITDA margin (excluding other income) was largely flat at 16.16% vs 16.29% a year ago. On a consolidated basis, revenue grew a strong 25.4% YoY to ₹116 crore, consolidated EBITDA margin expanded sharply to 11.88% from 7.59%, and the consolidated net loss narrowed to ₹87 lakh from ₹884 lakh. The board also approved the 32nd AGM for September 26, 2025, accepted the resignation of Director Sanjay Shah, appointed Alkesh Shah as additional director, and appointed M/s. Shah Mehta & Bakshi as statutory auditors for a five-year term.
Mixed picture for shareholders: standalone PAT slipped YoY despite steady revenue, but consolidated losses narrowed sharply with strong revenue growth and EBITDA margin expansion, driven by subsidiaries Innoxel Lifesciences and Varenyam Healthcare. Auditor change and director reshuffle are routine governance items, with no qualifications in the limited review report.